Linking diacylglycerol kinase to T cell anergy

Nature Immunology (Impact Factor: 20). 12/2006; 7(11):1132-4. DOI: 10.1038/ni1106-1132
Source: PubMed


Understanding of the signaling networks regulating T cell anergy remains incomplete. Two reports now demonstrate that alterations in diacylglycerol metabolism regulate the adoption of an anergic versus an activated T cell fate.

6 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The family of the Casitas B-lineage Lymphoma (Cbl) proteins, c-Cbl, Cbl-b, and Cbl-3, function as E3 ubiquitin ligases and molecular adaptors. In particular, Cbl-b acts as a gatekeeper in T cell activation that controls activation thresholds and the requirement for co-stimulation. Loss of Cbl-b expression renders animals susceptible to antigen-triggered autoimmunity suggesting that Cbl-b is a key autoimmunity gene. In addition, Cbl-b plays a critical role in T cell anergy and escape from regulatory T cells (Treg) suppression. Modulation of Cbl-b might provide us with a unique opportunity for future immune treatment of human disorders such as autoimmunity, immunodeficiency, or cancer.
    Seminars in Immunology 06/2007; 19(3):206-14. DOI:10.1016/j.smim.2007.02.004 · 5.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Monomorphic MHC class II determinants are attractive targets for immunomodulation. HLA-DR ligation on antigen-presenting cells (APCs) can dramatically alter their function or induce cell death. In monocytes, HLA-DR triggering diminishes their capacity to stimulate T cell proliferation. To further investigate this monocyte-dependent T cell inhibition, we activated human T cells +/- HLA-DR triggering on APCs and tested whether this can induce T cell anergy. Only anti-HLA-DR, but not anti-proliferative control agent anti-CD45, could modulate monocytes in primary cultures with stimulated T cells, so that T cells were hyporesponsive during re-stimulation. Cell separation studies demonstrated that HLA-DR ligation on monocytes is sufficient for mediating T cell anergy. Secretion of monokines was severely reduced after primary culture. Monocytes anergized independently of soluble factors. Extracellular signal-regulated kinase (ERK) phosphorylation occurred early with anti-HLA-DR, but late with anti-CD45 antibody. However, ERK inhibition did not reverse the T cell-anergizing potential of HLA-DR-ligated monocytes implicating other signaling pathways involved in tolerance induction. When analyzing the anergized T cells, they were refractory to exogenous IL-2 and characterized by defective secretion of various cytokines. Expression of CD25, CD28, intracellular CD3zeta and CTLA-4 was reduced. The hyporesponsive T cells up-regulated cell-cycle inhibitors p27(kip1) and p21(cip1) in correlation with human T cell anergy. In contrast, caspase-3 and -8, known to contribute to T cell proliferation, were equally decreased in anti-HLA-DR- and anti-CD45-inhibited cultures. In summary, anti-HLA-DR treatment can generate tolerogenic monocytes transmitting T cell anergy that may be exploited for future immunomodulatory strategies to treat immune-mediated disease states.
    International Immunology 05/2008; 20(4):601-13. DOI:10.1093/intimm/dxn019 · 2.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The E3 ubiquitin ligase Cbl-b, a member of the the family of the Cbl (Casitas B-lineage lymphoma) proteins, has been established as an important negative regulator of lymphocyte signalling. Genetic inactivation of Cbl-b revealed it to be a key autoimmunity gene. Cbl-b functions as a gatekeeper in T cell activation that controls activation thresholds and the requirement for co-stimulation. Importantly, Cbl-b deletion uncouples T cell activation from the requirement of CD28 co-stimulation, impairs anergy induction and reduces the sensitivity to regulatory T cell suppression. In consequence, Cbl-b-deficient animals display enhanced T cell proliferation and enhanced susceptibility to autoimmune diseases in various models in vitro and in vivo.
    The Epigenetics of Autoimmune Diseases, 04/2009: pages 75 - 94; , ISBN: 9780470743553
Show more


6 Reads
Available from